News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Drug interactions and pharmacokinetics news

Show

From To
Testing and health monitoring
Wide variability in drug levels casts doubt on the practicality of therapeutic drug monitoring

Levels of antiretroviral drugs vary considerably within HIV-positive patients, according to a small pharmacokinetic study from the United States published in the 15th April edition

Published
28 March 2006
By
Christopher Gadd
Drug interactions and pharmacokinetics
Unexpected interaction between heroin substitute and atazanavir/ritonavir

Atazanavir (Reyataz), boosted by low dose ritonavir (Norvir) appears to interact with the opiate substitute, buprenorphine. Doctors from Connecticut in the USA report a series

Published
27 March 2006
By
Michael Carter
Drug interactions and pharmacokinetics
Debate continues over interaction between ritonavir-boosted atazanavir and antacids

Three letters published in the March edition of The Journal of Acquired Immune Deficiency Syndromes have illustrated that there is still considerable uncertainty about whether

Published
22 March 2006
By
Christopher Gadd
Resistance
CROI: Saquinavir-based combination prevents mother-to-child HIV transmission

Short-term anti-HIV drug combinations including ritonavir (Norvir)-boosted saquinavir (Invirase) are more effective at reducing viral loads in the third trimester of pregnancy than nelfinavir (Viracept)-based

Published
22 February 2006
By
Christopher Gadd
Changing treatment
CROI: Simplified treatment regimens show promise in HIV-infected children

Two studies presented this morning at the Thirteenth Conference on Retroviruses and Opportunistic Infections in Denver have shown that simplified HIV drug regimens are safe

Published
07 February 2006
By
Christopher Gadd
Side-effects
Could interactions with other antiretrovirals cause ‘tenofovir-associated’ kidney disease?

Kidney disease in HIV-positive patients taking tenofovir (Viread) may be caused by interactions between tenofovir and other antiretrovirals, according to a group of doctors from

Published
25 January 2006
By
Christopher Gadd
HIV treatment
ICAAC: Dividing Triomune tablets may result in inadequate doses for small children; liquid best

The study was conducted in nine children receiving treatment at Lilongwe Central Hospital with a median age of 7.2 years and a median weight of

Published
06 January 2006
By
Keith Alcorn
Drug interactions and pharmacokinetics
ICAAC: Achillion reveals potential for once weekly dosing of nucleoside analogue

Elvucitabine, a new nucleoside analogue, has the potential for once-weekly dosing, according to results presented by manufacturer Achillion at the 45th Interscience Conference on Antimicrobial

Published
20 December 2005
By
Keith Alcorn
Drug interactions and pharmacokinetics
ICAAC: Nevirapine and rifampicin can be safely used together

Nevirapine-based antiretroviral therapy may be a safe and effective option for patients who need to take anti-tuberculosis treatment containing rifampicin at the same time as

Published
19 December 2005
By
Michael Carter
Drug interactions and pharmacokinetics
Are atazanavir levels reduced by antacids?

Levels of the protease inhibitor atazanavir (Reyataz) might not be lowered by taking antacid drugs, according to the results of a French pharmacokinetic study in

Published
24 October 2005
By
Christopher Gadd
← Prev1...2021222324Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.